**Additional File 1**

**Title:** Time trends of HIV-1 Drug Resistance in Portugal and its impact for first line treatment recommendations

**Statistical Analysis**

In the univariate analysis of factors associated with HIV drug resistance the following covariates were separately included: gender, age at diagnosis, risk groups, geographic region of origin, subtype, CD4 value and viral load. Factors significantly associated with TDR in a univariate analysis (p<0.05), factors with a p value less than 0.2[[1]](#footnote-1) and factors considered with biologic value (gender and age at diagnosis) were included into multiple logistic regression.

Patterns of TDR, ADR and for the prevalence of mutations over time were calculated by logistic regression, using R 3.5.1. For TDR, ADR and mutations the logistic regression model was calculated for each class of resistance, with Odds Ratio (OR) and 95% confidence intervals (CI). Results were considered statistically significant when p-values were below 0.05.

**Characteristics of Portuguese population**

Drug naïve patients were predominantly male (64.6%) and 34.5% were female. Median age at the time point of HIV genotyping resistance testing was 38.0 years (IQR: 31.0-48.0). The main mode of transmission was heterosexual contact (4.9%), followed by sex between men (2.6%) and by intravenous drug use (2.6%). For 88.8% of patients, mode of transmission was unknown. 67.3% of TP were male and 32.2% were female, presenting a median age of 39.0 years (IQR: 33.0-46.0) at the time of the drug resistance testing. Heterosexual contact (4.7%) was the most common mode of transmission, followed by intravenous drug use (4.5%), and by sex between men (1.8%). For 86.3% of treated patients mode of transmission was unknown. Both patients, DN and TP, were predominantly infected with subtype B (36.7% and 42.6%)), followed by subtype G (25.2% and 32.8%) and Circulating Recombinants Forms (CRFs) (22.2% and 16.5%). Most patients were born in Portugal (34.7% and 29.9%for DN and TP respectively). 17.4% of DN patients and 12.9% of TP were born abroad, most of them originating from Sub-Saharan Africa (13.3% and 11.1% for DN and TP, respectively). For 48.0% of patients, country of origin was unknown. At the time of HIV genotypic resistance testing, the median viral load (VL) for DN patients was 4.8Log10 copies/ml (IQR:4.2-5.4) and CD4 cell count was 321.5 (IQR:145.0-505.0). The median viral load for treated patients was 4.2 Log10 copies/ml (IQR:3.5-4.8) and CD4 cell count was 262 (IQR:136.0-440.0) (Table A in Additional File 1).

**Table A-** Demographic and clinic patient characteristics, 2001-2017

|  |  |  |
| --- | --- | --- |
| **Patient characteristics** | **ART naïve group** | **ART experienced group** |
| **Total, n (%)** | 7310 (100%) | 3848 (100%) |
| **Gender, n (%)** |  |  |
| Female | 2521 (34.5%) | 1239 (32.2%) |
| Male | 4719 (64.6%) | 2588 (67.3%) |
| **Median age at genotyping in years (IQR)** | 38.0 (31.0-48.0) | 39.0 (33.0-46.0) |
| 18-25 | 766 (10.5%) | 153 (4.0%) |
| 26-40 | 3287 (45.0%) | 1930 (50.2%) |
| 41-55 | 2263 (31.0%) | 1366 (35.5%) |
| >56 | 843 (11.5%) | 340 (8.8%) |
| **Mode of transmission, n (%)** |  |  |
| Heterosexuals | 358 (4.9%) | 181 (4.7%) |
| Men who have sex with men | 193 (2.6%) | 69 (1.8%) |
| Intravenous drug use | 189 (2.6%) | 173 (4.5%) |
| Others | 78 (1.1%) | 106 (2.8%) |
| Unknown | 6492 (88.8%) | 3319 (86.3%) |
| **Region of origin, n (%)** |  |  |
| Portugal | 2535 (34.7%) | 1152 (29.9%) |
| Subarian-Africa | 972 (13.3%) | 427 (11.1%) |
| South America | 201 (2.8%) | 46 (1.2%) |
| Europe | 81 (1.1%) | 20 (0.5%) |
| Others | 10 (0.1%) | 4 (0.1%) |
| Unknown | 3511 (48.0%) | 2199 (57.2%) |
| **Year of genotyping, n (%)** |  |  |
| 2001-2005 | 655 (9.0%) | 1555 (40.4%) |
| 2006-2009 | 1812 (24.8%) | 1226 (31.9%) |
| 2010-2013 | 2270 (31.1%) | 588 (15.3%) |
| 2014-2017 | 2573 (35.2%) | 479 (12.4%) |
| **HIV-1 subtype, n (%)** |  |  |
| Subtype B | 2686 (36.7%) | 1639 (42.6%) |
| Subtype G | 1845 (25.2%) | 1262 (32.8%) |
| Subtype C | 499 (6.8%) | 149 (3.9%) |
| Subtype A | 312 (4.3%) | 55 (1.4%) |
| Subtype F1 | 265 (3.6%) | 72 (1.9%) |
| Circulating Recombinants Forms (CRFs) | 1621 (22.2%) | 635 (16.5%) |
| Other HIV-1 subtypes | 67 (0.92%) | 28 (0.7%) |
| **CD4 count at time of resistance test** (cells/mL) |  |  |
| Median CD4 count  (IQR; range) | 321.5 (145.0- 505.0)  (0.0-1905.0) | 262.0 (136.0-440.0)  (0.0-1844.0) |
| <50 | 415 (5.7%) | 308 (8.0%) |
| 51-200 | 762 (10.4%) | 868 (22.6%) |
| 201-350 | 807 (11.0%) | 817 (21.2%) |
| 351-500 | 735 (10.1%) | 533 (13.9%) |
| 501 | 929 (12.7%) | 565 (14.7%) |
| Unknown | 3662 (50.1%) | 757 (19.7%) |
| **Viral Load at time of resistance test** (log10 copies/ml) |  |  |
| Median Log Viral Load (IQR) | 4.8 (4.2-5.4) | 4.2 (3.5-4.8) |
| < 4.0 | 1111 (15.2%) | 1526 (39.7%) |
| 4.1 to 5.0 | 2354 (32.2%) | 1227 (31.9%) |
| >5.1 | 2187 (29.9%) | 620 (16.1%) |
| Unknown | 1658 (22.7%) | 475 (12.3%) |

**Table B**- Trends of transmitted drug resistance between 2006 and 2017, 2014 and 2017 and September 2014 and December 2017 and of acquired drug resistance between 2001 and 2017

|  |  |  |  |
| --- | --- | --- | --- |
| **Years** | **Transmitted drug resistance (TDR)** | **OR (95% CI)** | **p for trend** |
| **2006-2017** | Any DRMs | 1.005 (1.003-1.007) | <0.001 |
|  | NRTI resistance | 1.004 (1.002-1.005) | <0.001 |
|  | NNRTI resistance | 1.004 (1.002-1.005) | <0.001 |
|  | PI resistance | 1.001 (0.999-1.002) | 0.164 |
|  | Single class resistance | 1.005 (1.002-1.006) | <0.001 |
|  | Dual classes resistance | 1.000 (0.999-1.001) | 0.604 |
|  | PI + NRTI resistance | 1.001 (1.000-1.001) | 0.011 |
|  | PI + NNRTI resistance | 1.000 (0.999-1.001) | 0.490 |
|  | NRTI+NNRTI resistance | 1.003 (1.002-1.003) | <0.001 |
|  | Triple class resistance | 1.000 (1.000-1.001) | 0.037 |
| **2014-2017** | Any DRMs | 1.015 (1.004-1.026) | 0.008 |
|  | NRTI resistance | 1.013 (1.005-1.021) | <0.001 |
|  | NNRTI resistance | 1.013 (1.004-1.021) | 0.005 |
|  | PI resistance | 0.998 (0.993-1.004) | 0.595 |
|  | Single class resistance | 1.013 (1.002-1.023) | 0.020 |
|  | Dual classes resistance | 1.001 (0.998-1.003) | 0.534 |
|  | PI + NRTI resistance | 1.002 (0.999-1.004) | 0.272 |
|  | PI + NNRTI resistance | 1.002 (0.999-1.005) | 0.072 |
|  | NRTI+NNRTI resistance | 1.007 (1.001-1.012) | 0.019 |
|  | Triple class resistance | 1.002 (0.999-1.004) | 0.125 |
| **Sep 2015-2017** | Any DRMs | 1.008 (0.984-1.033) | 0.507 |
|  | NRTI resistance | 1.004 (0.986-1.022) | 0.691 |
|  | NNRTI resistance | 1.015 (0.995-1.035) | 0.140 |
|  | PI resistance | 0.994 (0.982-1.006) | 0.327 |
|  | Single class resistance | 1.008 (0.984-1.032) | 0.524 |
|  | Dual classes resistance | 0.999 (0.993-1.005) | 0.688 |
|  | PI + NRTI resistance | 1.001 (0.994-1.007) | 0.802 |
|  | PI + NNRTI resistance | 1.002 (0.996-1.008) | 0.587 |
|  | NRTI+NNRTI resistance | 1.003 (0.990-1.017) | 0.612 |
|  | Triple class resistance | 1.002 (0.997-1.007) | 0.432 |
| **Years** | **Acquired drug resistance (ADR)** | **OR (95% CI)** | **p for trend** |
| **Sep 2015-2017** | Any DRMs | 0.990 (0.904-1.085) | 0.836 |
|  | NRTI resistance | 0.914 (0.836-0.998) | 0.047 |
|  | NNRTI resistance | 1.001 (0.924-1.103) | 0.828 |
|  | PI resistance | 1.038 (0.988-1.091) | 0.142 |
|  | Single class resistance | 1.056 (0.977-1.139) | 0.171 |
|  | Dual classes resistance | 0.904 (0.836-0.976) | 0.011 |
|  | PI + NRTI resistance | 1.030 (0.985-1.078) | 0.194 |
|  | PI + NNRTI resistance | 1.037 (0.999-1.074) | 0.052 |
|  | NRTI+NNRTI resistance | 0.941 (0.867-1.021) | 0.145 |
|  | Triple class resistance | 1.039 (1.004-1.075) | 0.029 |

**Table C**- Proportion of transmitted drug resistance and of acquired drug resistance for single, double and triple classes and for associations of drug classes between 2001 and 2017

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **ART-Naive group** | | | | | | | **ART-treated group** | | | | | | |
|  | **Single class** | **Double Class** | **Triple Class** | **NRTIs + NNRTIs** | **NRTIs+PIs** | **NNRTIs+PIs** | **Single class** | | **Double Class** | **Triple Class** | **NRTIs+ NNRTIs** | **NRTIs+PIs** | **NNRTIs+PIs** |
| 2001 | 6 (13.3%) | 3 (6.7%) | 3 (6.7%) | 5 (11.1%) | 5 (11.1%) | 4 (8.9%) | 100 (44.6%) | | 44 (19.6%) | 50 (22.3%) | 92 (41.1%) | 115 (51.3%) | 52 (23.2%) |
| 2002 | 4 (5.7%) | 2 (2.9%) | 0 (0.0%) | 0 (0.0%) | 2 (2.9%) | 0 (0.0%) | 167 (48.4%) | | 58 (16.8%) | 78 (22.6%) | 135 (39.1%) | 175 (50.7%) | 79 (22.9%) |
| 2003 | 13 (5.2%) | 5 (2.0%) | 2 (0.8%) | 4 (1.6%) | 7 (2.8%) | 2 (0.8%) | 100 (35.5%) | | 101(35.8%) | 45 (16.0%) | 142 (50.4%) | 92 (32.6%) | 49 (17.4%) |
| 2004 | 8 (5.1%) | 2 (1.3%) | 0 (0.0%) | 1 (0.6%) | 2 (1.3%) | 0 (0.0%) | 145 (37.5%) | | 146 (37.7%) | 41 (10.6%) | 184 (47.5%) | 103 (26.6%) | 44 (11.4%) |
| 2005 | 13 (9.8%) | 3 (2.3%) | 1 (0.8%) | 4 (3.0%) | 4 (3.0%) | 1 (0.8%) | 97 (30.6%) | | 105 (33.1%) | 36 (11.4%) | 139 (43.8%) | 73 (23.0%) | 38 (12.0%) |
| 2006 | 9 (4.7%) | 1 (0.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) | 103 (27.8%) | | 135 (36.4%) | 40 (10.8%) | 175 (47.2%) | 80 (21.6%) | 40 (10.8%) |
| 2007 | 23 (5.5%) | 2 (0.5%) | 0 (0.0%) | 1 (0.2%) | 1 (0.2%) | 1 (0.2%) | 86 (29.0%) | | 83 (27.9%) | 25 (8.4%) | 103 (34.7%) | 51 (17.2%) | 30 (10.1%) |
| 2008 | 51 (8.8%) | 2 (0.3%) | 2 (0.3%) | 9 (1.5%) | 2 (0.3%) | 4 (0.7%) | 66 (25.9%) | | 57 (22.4%) | 11 (4.3%) | 67 (26.3%) | 26 (10.2%) | 12 (4.7%) |
| 2009 | 44 (7.1%) | 3 (0.5%) | 0 (0.0%) | 6 (1.0%) | 1 (0.2%) | 2 (0.3%) | 86 (28.4%) | | 67 (22.1%) | 16 (5.3%) | 82 (27.1%) | 31 (10.2%) | 17 (5.6%) |
| 2010 | 53 (8.2%) | 2 (0.3%) | 1 (0.2%) | 3 (0.5%) | 1 (0.2%) | 3 (0.5%) | 73 (30.7%) | | 50 (21.0%) | 6 (2.5%) | 56 (23.5%) | 17 (7.1%) | 6 (2.5%) |
| 2011 | 46 (7.0%) | 6 (0.9%) | 0 (0.0%) | 2 (0.3%) | 4 (0.6%) | 2 (0.3%) | 45 (30.8%) | | 29 (19.9%) | 6 (4.1%) | 34 (23.3%) | 13 (8.9%) | 7 (4.8%) |
| 2012 | 41 (9.6%) | 1 (0.2%) | 0 (0.0%) | 2 (0.5%) | 0 (0.0%) | 1 (0.2%) | 37 (35.2%) | | 24 (22.9%) | 1 (1.0%) | 24 (22.9%) | 7 (6.7%) | 2 (1.9%) |
| 2013 | 58 (10.6%) | 2 (0.4%) | 0 (0.0%) | 5 (0.9%) | 1 (0.2%) | 1 (0.2%) | 26 (26.3%) | | 22 (22.2%) | 3 (3.0%) | 24 (24.2%) | 7 (7.1%) | 4 (4.0%) |
| 2014 | 50 (8.4%) | 2 (0.3%) | 0 (0.0%) | 9 (1.5%) | 2 (0.3%) | 0 (0.0%) | 37 (25.0%) | | 36 (24.3%) | 5 (3.4%) | 40 (27.0%) | 11 (7.4%) | 6 (4.1%) |
| 2015 | 57 (8.9%) | 3 (0.5%) | 2 (0.3%) | 15 (2.4%) | 4 (0.6%) | 3 (0.5%) | 28 (22.8%) | | 25 (20.3%) | 9 (7.3%) | 34 (27.6%) | 14 (11.4%) | 9 (7.3%) |
| 2016 | 73 (10.2%) | 6 (0.8%) | 3 (0.4%) | 18 (2.5%) | 6 (0.8%) | 6 (0.8%) | 24 (22.6%) | | 29 (27.4%) | 2 (1.9%) | 30 (28.3%) | 6 (5.7%) | 3 (2.8%) |
| 2017 | 76 (12.2%) | 3 (0.5%) | 3 (0.5%) | 23 (3.7%) | 5 (0.8%) | 4 (0.6%) | 27 (26.5%) | | 18 (17.6%) | 7 (6.9%) | 25 (24.5%) | 9 (8.8%) | 7 (6.9%) |

**Table D-** Time trends of selected mutations with prevalence greater than 0.5% for drug-naïve patients and 5.0% for treated patients

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Drug-Naive Patients** | | | | | | | | | | | | | | | | | | | |
|  | **2001**  **(12)** | **2002**  **(6)** | **2003**  **(20)** | **2004**  **(10)** | **2005**  **(17)** | **2006**  **(10)** | **2007**  **(25)** | **2008**  **(55)** | **2009**  **(47)** | **2010**  **(56)** | **2011**  **(52)** | **2012**  **(42)** | **2013**  **(60)** | **2014**  **(52)** | **2015**  **(62)** | **2016**  **(82)** | **2017**  **(82)** | **OR (95%CI)** | **P trend** |
| **PIs- Protease Inhibitors (n/%)** | | | | | | | | | | | | | | | | | | | |
| **L90M** | 6  (50.0) | 1  (16.7) | 5  (25.0) | 3  (30.0) | 2  (11.8) | 0  (0.0%) | 3  (12.0) | 8  (14.5) | 5  (10.6) | 4  (7.1) | 10  (19.2) | 3  (7.1) | 7  (11.7) | 6  (11.5) | 7  (11.3) | 10  (12.2) | 5  (6.1) | 0.991  (0.985-0.997) | 0.002 |
| **M46IL** | 1  (8.3) | 1  (16.7) | 3  (15.0) | 1  (10.0) | 3  (17.6) | 1  (10.0) | 1  (4.0) | 4  (7.3) | 3  (6.4) | 8  (14.3) | 5  (9.6) | 2  (4.8) | 4  (6.7) | 5  (9.6) | 1  (1.6%) | 7  (8.5) | 4  (4.9%) | 0.995  (0.991-1.000) | 0.065 |
| **NNRTIs- Non-nucleoside reverse transcriptase inhibitors** **(n/%)** | | | | | | | | |  | | | | | | | | |  |  |
| **K103NS** | 5  (41.7) | 0  (0.0) | 3  (15.0) | 5  (50.0) | 5  (29.4) | 4  (40.0) | 9  (36.0) | 18  (32.7) | 16  (34.0) | 21  (37.5) | 11  (21.2) | 9  (21.4) | 18  (30.0) | 21  (40.4) | 20  (32.3) | 31  (37.8) | 39  (47.6) | 1.009  (1.000-1.018) | 0.040 |
| **G190ASEQ** | 2  (16.7) | 0  (0.0) | 3  (15.0) | 0  (0.0) | 2  (11.8) | 1  (10.0) | 2  (8.0) | 5  (9.1) | 3  (6.4) | 7  (12.5) | 5  (9.6) | 2  (4.8) | 4  (6.7) | 6  (11.5) | 10  (16.1) | 7  (8.5) | 10  (12.2) | 1.001  (0.996-1.007) | 0.618 |
| **K101EP** | 2  (16.7) | 0  (0.0) | 1  (5.0) | 0  (0.0) | 1  (5.9) | 1  (10.0) | 2  (8.0) | 6  (10.9) | 5  (10.6) | 6  (10.7) | 2  (3.8) | 2  (4.8) | 1  (1.7) | 2  (3.8) | 5  (8.1) | 5  (6.1) | 4  (4.9) | 0.997  (0.993- 1.002) | 0.201 |
| **Y181CIV** | 3  (25.0) | 0  (0.0) | 1  (5.0) | 0  (0.0) | 1  (5.9) | 0  (0.0) | 0  (0.0) | 5  (9.1) | 4  (8.5) | 3  (5.4) | 3  (5.8) | 1  (2.4) | 0  (0.0) | 2  (3.8) | 7  (11.3) | 9  (11.0) | 2  (2.4) | 0.999  (0.995-1.004) | 0.770 |
| **NRTIs- Nucleoside reverse transcriptase inhibitors** **(n/%)** | | | | | | | | |  | | | | | | | | |  |  |
| **M184VI** | 4  (33.3) | 4  (66.7) | 6  (30.0) | 1  (10.0) | 3  (17.6) | 0  (0.0) | 2  (8.0) | 7  (12.7) | 5  (10.6) | 2  (3.6) | 3  (5.8) | 0  (0.0) | 5  (8.3) | 6  (11.5) | 11  (17.7) | 13  (15.9) | 25  (30.5) | 1.002  (0.996-1.009) | 0.474 |
| **M41L** | 4  (33.3) | 2  (33.3) | 7  (35.0) | 2  (20.0) | 7  (41.2) | 1  (10.0) | 2  (8.0) | 8  (14.5) | 4  (8.5) | 5  (8.9) | 8  (15.4) | 9  (21.4) | 7  (11.7) | 5  (9.6) | 17  (27.4) | 14  (17.1) | 15  (18.3) | 0.997  (0.990-1.004) | 0.349 |
| **D67NGE** | 5  (41.7) | 0  (0.0) | 2  (10.0) | 0  (0.0) | 3  (17.6) | 1  (10.0) | 0  (0.0) | 7  (12.7) | 4  (8.5) | 6  (10.7) | 3  (5.8) | 0  (0.0) | 1  (1.7) | 3  (5.8) | 4  (6.5) | 2  (2.4) | 7  (8.5) | 0.993  (0.989-0.998) | 0.004 |
| **T215** **YFISCDVE** | 5  (41.7) | 1  (16.7) | 3  (15.0) | 1  (10.0) | 5  (29.4) | 0  (0.0) | 0  (0.0) | 2  (3.6) | 1  (2.1) | 0  (0.0) | 1  (1.9) | 0  (0.0) | 1  (1.7) | 2  (3.8) | 6  (9.7) | 3  (3.7) | 11  (13.4) | 0.996  (0.992-1.000) | 0.082 |
| **L210W** | 2  (16.7) | 1  (16.7) | 3  (15.0) | 2  (20.0) | 1  (5.9) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 1  (1.8) | 1  (1.9) | 2  (4.8) | 4  (6.7) | 4  (7.7) | 3  (4.8) | 5  (6.1) | 5  (6.1) | 0.999  (0.995-1.003) | 0.688 |
| **K219QERN** | 2  (16.7) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 4  (23.5) | 1  (10.0) | 1  (4.0) | 5  (9.1) | 4  (8.5) | 5  (8.9) | 4  (7.7) | 1  (2.4) | 2  (3.3) | 3  (5.8) | 6  (9.7) | 5  (6.1) | 10  (12.2) | 1.000  (0.996-1.005) | 0.895 |
| **Treated Patients** | | | | | | | | | | | | | | | | | | | |
| **PIs- Protease Inhibitors (n/%)** | | | | | | | | | | | | | | | | | | | |
|  | **2001**  **(197)** | **2002**  **(303)** | **2003**  **(246)** | **2004**  **(332)** | **2005**  **(238)** | **2006**  **(278)** | **2007**  **(194)** | **2008**  **(134)** | **2009**  **(169)** | **2010**  **(129)** | **2011**  **(80)** | **2012**  **(62)** | **2013**  **(51)** | **2014**  **(78)** | **2015**  **(62)** | **2016**  **(55)** | **2017**  **(52)** | **OR (95%CI)** | **P trend** |
| **M46IL** | 46  (23.7) | 66  (21.8) | 40  16.3) | 33  (9.9) | 30  (12.6) | 42  (15.1) | 27  (13.9) | 13  (9.7) | 16  (9.5) | 9  (7.0) | 8  (10.0) | 2  (3.2) | 3  (5.9) | 7  (9.0) | 7  (11.3) | 2  (3.6) | 7  (13.5) | 0.991  (0.988-0.994) | <0.001 |
| **I54VLMTAS** | 49  (25.3) | 81  (26.7) | 37  (15.0) | 44  (13.3) | 36  (15.1) | 34  (12.2) | 26  (13.4) | 13  (9.7) | 20  (11.8) | 5  (3.9) | 7  (8.8) | 3  (4.8) | 3  (5.9) | 6  (7.7) | 5  (8.1) | 3  (5.5) | 5  (9.6) | 0.988  (0.984-0.991) | <0.001 |
| **V82ATSF** | 43  (22.2) | 70  (23.1) | 35  (14.2) | 35  (10.5) | 28  (11.8) | 28  (10.1) | 18  (9.3) | 9  (6.7) | 15  (8.9) | 7  (5.4) | 4  (5.0) | 3  (4.8) | 2  (3.9) | 3  (3.8) | 3  (4.8) | 2  (3.6) | 4  (7.7) | 0.988  (0.985-0.991) | <0.001 |
| **L90M** | 69  (35.6) | 97  (32.0) | 49  (19.9) | 52  (15.7) | 41  (17.2) | 37  (13.3) | 26  (13.4) | 13  (9.7) | 10  (5.9) | 6  (4.7) | 8  (10.0) | 4  (6.5) | 6  (11.8) | 5  (6.4) | 5  (8.1) | 3  (5.5) | 4  (7.7) | 0.982  (0.979-0.985) | <0.001 |
| **NNRTIs- Non-nucleoside reverse transcriptase inhibitors** **(n/%)** | | | | | | | | | | | | | | | | | | | |
| **K103NS** | 53  (27.3) | 83  (27.4) | 80  (32.5) | 131  (39.5) | 111  (46.6) | 119  (42.8) | 94  (48.5) | 52  (38.8) | 74  (43.8) | 46  (35.7) | 24  (30.0) | 25  (40.3) | 20  (39.2) | 25  (32.1) | 23  (37.1) | 18  (32.7) | 24  (46.2) | 1.005  (1.001-1.010) | 0.020 |
| **Y181CIV** | 37  (19.1) | 32  (10.6) | 44  (17.9) | 47  (14.2) | 32  (13.4) | 38  (13.7) | 18  (9.3) | 19  (14.2) | 14  (8.3) | 27  (20.9) | 12  (15.0) | 6  (9.7) | 3  (5.9) | 22  (28.2) | 6  (9.7) | 10  (18.2) | 9  (17.3) | 1.001  (0.997-1.004) | 0.728 |
| **G190ASE** | 24  (12.4) | 35  (11.6) | 37  (15.0) | 38  (11.4) | 39  (16.4) | 46  (16.5) | 26  (13.4) | 19  (14.2) | 22  (13.0) | 16  (12.4) | 10  (12.5) | 6  (9.7) | 7  (13.7) | 10  (12.8) | 7  (11.3) | 10  (18.2) | 4  (7.7) | 0.999  (0.997-1.003) | 0.819 |
| **K101PEH** | 18  (9.3) | 20  (6.6) | 20  (8.1) | 27  (8.1) | 21  (8.8) | 27  (9.7) | 20  (10.3) | 13  (9.7) | 17  (10.1) | 7  (5.4) | 5  (6.3) | 3  (4.8) | 1  (2.0) | 3  (3.8) | 5  (8.1) | 8  (14.5) | 1  (1.9) | 0.999  (0.996-1.001) | 0.314 |
| **NRTIs- Nucleoside reverse transcriptase inhibitors** **(n/%)** | | | | | | | | | | | | | | | | | | | |
| **M41L** | 76  (39.2) | 119  (39.3) | 80  (32.5) | 85  (25.6) | 64  (26.9) | 62  (22.3) | 38  (19.6) | 18  (13.4) | 27  (16.0) | 6  (4.7) | 8  (10.0) | 8  (12.9) | 4  (7.8) | 5  (6.4) | 5  (8.1) | 6  (10.9) | 6  (11.5) | 0.977  (0.973-0.981) | <0.001 |
| **D67NGE** | 75  (38.7) | 112  (37.0) | 67  (27.2) | 80  (24.1) | 68  (28.6) | 69  (24.8) | 39  (20.1) | 27  (20.1) | 22  (13.0) | 13  (10.1) | 12  (15.0) | 4  (6.5) | 9  (17.6) | 9  (11.5) | 6  (9.7) | 5  (9.1) | 8  (15.4) | 0.981  (0.977-0.985) | <0.001 |
| **K70R** | 39  (20.1) | 54  (17.8) | 32  (13.0) | 49  (14.8) | 44  (18.5) | 43  (15.5) | 24  (12.4) | 16  (11.9) | 9  (5.3) | 5  (3.9) | 9  811.3) | 2  (3.2) | 3  (5.9) | 2  (2.6) | 3  (4.8) | 5  (9.1) | 5  (9.6) | 0.990  (0.987-0.993) | <0.001 |
| **L210W** | 37  (19.1) | 50  (16.5) | 41  (16.7) | 29  (8.7) | 23  (9.7) | 21  (7.6) | 18  (9.3) | 7  (5.2) | 8  (4.7) | 1  (0.8) | 1  (1.3) | 1  (1.6) | 1  (2.0) | 1  (1.3) | 1  (1.6) | 2  (3.6) | 1  (1.9) | 0.988  (0.985-0.990) | <0.001 |
| **T215YF** | 90  (46.4) | 139  (45.9) | 93  (37.8) | 96  (28.9) | 73  (30.7) | 57  (20.5) | 41  (21.1) | 22  (16.4) | 23  (13.6) | 9  (7.0) | 11  (13.8) | 5  (8.1) | 4  (7.8) | 6  (7.7) | 4  (6.5) | 3  (5.5) | 8  (15.4) | 0.972  (0.968-0.975) | <0.001 |
| **K219QE** | 58  (29.9) | 76  (25.1) | 57  (23.2) | 55  (16.6) | 59  (24.8) | 52  (18.7) | 40  (20.6) | 22  (16.4) | 15  (8.9) | 10  (7.8) | 10  (12.5) | 5  (8.1) | 4  (7.8) | 11  (14.1) | 12  (19.4) | 13  (23.6) | 9  (17.3) | 0.990  (0.987-0.994) | <0.001 |
| **M184IV** | 129  (66.5) | 185  (61.1) | 159  (64.6) | 220  (66.3) | 160  (67.2) | 199  (71.6) | 136  (70.1) | 93  (69.4) | 107  (63.3) | 78  (60.5) | 47  (58.8) | 38  (61.3) | 34  (68.6) | 51  (65.4) | 40  (66.1) | 39  (70.9) | 29  (55.8) | 0.999  (0.995-1.003) | 0.639 |
| **L74IV** | 13  (6.7) | 20  (6.6) | 18  (7.3) | 17  (5.1) | 9  (3.8) | 19  (6.8) | 8  (4.1) | 8  (6.0) | 8  (4.7) | 6  (4.7) | 4  (5.0) | 1  (1.6) | 2  (3.9) | 6  (7.7) | 2  (3.2) | 6  (10.9) | 2  (3.8) | 0.999  (0.997-1.001) | 0.379 |

**Table E**- Univariate analysis of factors associated with HIV transmitted drug resistance

|  | **Any TDR** | | | | | | | **NRTI TDR** | | | | | | **NNRTI TDR** | | | | | | **PI TDR** | |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **n (%)** | | | **OR (95%CI)** | | | **p** | **n (%)** | **OR (95%CI)** | | **p** | | | | **n (%)** | | **OR (95%CI)** | | **p** | | **n (%)** | **OR (95%CI)** | **p** |
| **Gender** |  | | |  | | |  |  |  | |  | | | |  | |  | |  | |  |  |  |
| Female \* | 215 (31.2%) | | |  | | |  | 92 (31.8%) |  | |  | | | | 135 (36.8%) | |  | |  | | 50 (24.3%) |  |  |
| Male | 467 (67.7%) | | | 1.18 (0.99-1.40) | | | 0.058 | 193 (66.8%) | 1.13 (0.87-1.45) | | 0.359 | | | | 228 (62.1%) | | 0.90 (0.72-1.12) | | 0.331 | | 155 (75.2%) | 1.68 (1.22-2.32) | 0.002 |
| **Age at diagnosis** |  | | |  | | |  |  |  | |  | | | |  | |  | |  | |  |  |  |
| 18-25\* | 68 (9.9%) | | |  | | |  | 22 (7.6%) |  | |  | | | | 38 (10.4%) | |  | |  | | 19 (9.2%) |  |  |
| 26-40 | 291 (42.2%) | | | 1.00 (0.76-1.32) | | | 0.983 | 108 (37.4%) | 1.15 (0.72-1.83) | | 0.559 | | | | 151 (41.1%) | | 0.92 (0.64-1.33) | | 0.665 | | 93 (45.1%) | 1.14 (0.69-1.89) | 0.596 |
| 41-55 | 223 (32.3%) | | | 1.12 (0.84-1.49) | | | 0.428 | 110 (38.1%) | 1.73 (1.08-2.75) | | 0.021 | | | | 114 (31.1%) | | 1.02 (0.70-1.48) | | 0.933 | | 60 (29.1%) | 1.07 (0.64-1.81) | 0.798 |
| >56 | 80 (11.6%) | | | 1.08 (0.77-1.51) | | | 0.671 | 29 (10.0%) | 1.20 (0.69-2.12) | | 0.517 | | | | 44 (12.0%) | | 1.06 (0.68-1.65) | | 0.814 | | 29 (14.1%) | 1.40 (0.78-2.52) | 0.261 |
| **Risk groups** |  | | |  | | |  |  |  | |  | | | |  | |  | |  | |  |  |  |
| Heterosexuals\* | 38 (5.5%) | | |  | | |  | 17 (5.9%) |  | |  | | | | 23 (6.3%) | |  | |  | | 11 (5.3%) |  |  |
| MSM | 18 (2.6%) | | | 0.87 (0.48-1.56) | | | 0.633 | 6 (2.1%) | 0.64 (0.25-1.66) | | 0.362 | | | | 6 (1.6%) | | 0.47 (0.19-1.17) | | 0.104 | | 8 (3.9%) | 1.36 (0.54-3.45) | 0.512 |
| IVDU | 19 (2.8%) | | | 0.94 (0.53-1.68) | | | 0.838 | 9 (3.1%) | 1.00 (0.44-2.30) | | 0.994 | | | | 9 (2.5%) | | 0.73 (0.33-1.61) | | 0.432 | | 6 (2.9%) | 1.03 (0.38-2.84) | 0.948 |
| Others | 5 (0.7%) | | | 0.58 (0.22-1.52) | | | 0.264 | 3 (1.0%) | 0.80 (0.23-2.80) | | 0.730 | | | | 1 (0.3%) | | 0.19 (0.02-1.42) | | 0.106 | | 3 (1.5%) | 1.26 (0.24-4.63) | 0.726 |
| **Geographic region of origin** |  | | |  | | |  |  |  | |  | | | |  | |  | |  | |  |  |  |
| Portugal\* | 249 (36.1%) | | |  | | |  | 98 (33.9%) |  | |  | | | | 121 (33.0%) | |  | |  | | 95 (46.1%) |  |  |
| Europe | 5 (0.7%) | | | 0.60 (0.24-1.51) | | | 0.280 | 4 (1.4%) | 1.29 (0.46-3.60) | | 0.624 | | | | 2 (0.5%) | | 0.50 (0.12-2.08) | | 0.344 | | 0 (0.0%) | ------ | ------ |
| Sub-Saharan Africa | 88 (12.8%) | | | 0.91 (0.71-1.18) | | | 0.489 | 45 (15.6%) | 1.21 (0.84-1.73) | | 0.307 | | | | 11 (3.0%) | | 1.31 (0.95-1.80) | | 0.094 | | 10 (4.9%) | 0.27 (0.14-0.51) | 0.000 |
| South America | 20 (2.9%) | | | 1.01 (0.63-1.64) | | | 0.953 | 6 (2.1) | 0.76 (0.33-1.77) | | 0.531 | | | | 11 (3.0%) | | 1.16 (0.61-2.18) | | 0.656 | | 1 (0.5%) | 0.52 (0.19-1.43) | 0.207 |
| **Subtypes** |  | | |  | | |  |  |  | |  | | | |  | |  | |  | |  |  |  |
| B\* | 304 (44.1%) | | |  | | |  | 141 (48.8%) |  | |  | | | | 129 (35.1%) | |  | |  | | 105 (51.0%) |  |  |
| Non-B | 240 (34.8%) | | | 0.70 (0.59-0.84) | | | 0.000 | 78 (27.0%) | 0.50 (0.37-0.66) | | 0.000 | | | | 164 (44.7%) | | 1.18 (0.93-1.49) | | 0.173 | | 62 (30.1%) | 0.53 (0.389-0.73) | 0.000 |
| **CD4** (cells/mL) |  | | |  | | |  |  |  | |  | | | |  | |  | |  | |  |  |  |
| <50\* | 36 (5.2%) | | |  | | |  | 18 (6.2%) |  | |  | | | | 20 (5.4%) | |  | |  | | 10 (4.9%) |  |  |
| 51-200 | 63 (9.1%) | | | 0.95 (0.62-1.46) | | | 0.810 | 23 (8.0%) | 0.69 (0.37-1.29) | | 0.241 | | | | 40 (10.9%) | | 1.09 (0.63-1.90) | | 0.749 | | 15 (7.3%) | 0.81 (0.36-1.83) | 0.617 |
| 201-350 | 72 (10.4%) | | | 1.03 (0.68-1.57) | | | 0.885 | 29 (10.0%) | 0.82 (0.45-1.50) | | 0.523 | | | | 39 (10.6%) | | 1.00 (0.58-1.74) | | 0.992 | | 22 (10.7%) | 1.14 (0.53-2.42) | 0.743 |
| 351-500 | 75 (10.9%) | | | 1.20 (0.79-1.81) | | | 0.399 | 23 (8.0%) | 0.71 (0.38-1.34) | | 0.291 | | | | 45 (12.3%) | | 1.29 (0.75-2.21) | | 0.357 | | 27 (13.1%) | 1.54 (0.74-3.22) | 0.247 |
| >501 | 100 (14.5%) | | | 1.27 (0.85-1.89) | | | 0.241 | 39 (13.5%) | 0.97 (0.55-1.71) | | 0.907 | | | | 49 (13.4%) | | 1.10 (0.64-1.88) | | 0.727 | | 33 (16.0%) | 1.49 (0.73-3.06) | 0.247 |
| **Viral Load** (log10 copies/ml) |  | | |  | | |  |  |  | |  | | | |  | |  | |  | |  |  |  |
| < 4.0\* | 128 (18.6%) | | |  | | |  | 65 (22.5%) |  | |  | | | | 76 (20.7%) | |  | |  | | 41 (19.9%) |  |  |
| 4.1 to 5.0 | 216 (31.3%) | | | 0.78 (0.62-0.98) | | | 0.032 | 80 (27.7%) | 0.57 (0.40-0.79) | | 0.001 | | | | 112 (30.5%) | | 0.68 (0.50-0.92) | | 0.012 | | 71 (34.5%) | 0.81 (0.55-1.20) | 0.296 |
| >5.1 | 176 (25.5%) | | | 0.67 (0.53-0.86) | | | 0.001 | 64 (22.1%) | 0.48 (0.34-0.69) | | 0.000 | | | | 91 (24.8%) | | 0.59 (0.43-0.81) | | 0.001 | | 46 (22.3%) | 0.56 (0.37-0.86) | 0.008 |
| **\* Reference category** | |  |  | |  |  |  |  |  |  | |  |  | | |  | |

**Table F**- Univariate analysis of factors associated with HIV acquired drug resistance

|  | **Any ADR** | | | | | | | **NRTI ADR** | | | | | | | **NNRTI ADR** | | | **PI ADR** |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **n (%)** | | | **OR (95%CI)** | | | **p** | **n (%)** | **OR (95%CI)** | | **p** | | | | **n (%)** | **OR (95%CI)** | **p** | **n (%)** | **OR (95%CI)** | **p** |
| **Gender** |  | | |  | | |  |  |  | |  | | | |  |  |  |  |  |  |
| Female \* | 787 (29.7%) | | |  | | |  | 641 (22.8%) |  | |  | | | | 538 (30.5%) |  |  | 208 (22.9%) |  |  |
| Male | 1861 (70.0%) | | | 1.45 (1.27-1.70) | | | 0.000 | 1575 (70.8%) | 1.45 (1.26-1.66) | | 0.000 | | | | 1217 (69.0%) | 1.16 (1.01-1.33) | 0.036 | 699 (76.9%) | 1.83 (1.54-2.18) | 0.000 |
| **Age at diagnosis** |  | | |  | | |  |  |  | |  | | | |  |  |  |  |  |  |
| 18-25\* | 89 (3.3%) | | |  | | |  | 18 (2.0%) |  | |  | | | | 67 (3.8%) |  |  | 18 (2.0%) |  |  |
| 26-40 | 1336 (50.3%) | | | 1.62 (1.15-2-26) | | | 0.005 | 443 (48.7%) | 1.44 (1.04-2.00) | | 0.030 | | | | 886 (50.3%) | 1.09 (0.78-1.52) | 0.613 | 443 (48.7%) | 2.23 (1.35-3.70) | 0.002 |
| 41-55 | 937 (35.3%) | | | 1.57 (1.12-2.21) | | | 0.009 | 332 (36.5%) | 1.45 (1.04-2.03) | | 0.029 | | | | 621 (35.2%) | 1.07 (0.76-1.50) | 0.694 | 332 (36.5%) | 2.41 (1.45-4.00) | 0.001 |
| >56 | 252 (9.5%) | | | 2.06 (1.38-3.08) | | | 0.000 | 103 (11.3%) | 1.93 (1.31-2.84) | | 0.001 | | | | 160 (9.1%) | 1.14 (0.78-1.68) | 0.501 | 103 (11.3%) | 3.26 (1.89-5.61) | 0.000 |
| **Risk groups** |  | | |  | | |  |  |  | |  | | | |  |  |  |  |  |  |
| Heterosexuals\* | 139 (5.2%) | | |  | | |  | 74 (3.3%) |  | |  | | | | 83 (4.7%) |  |  | 56 (6.2%) |  |  |
| MSM | 42 (1.6%) | | | 0.47 (0.26-0.85) | | | 0.013 | 1108 (49.8%) | 0.38 (0.22-0.67) | | 0.001 | | | | 27 (1.5%) | 0.76 (0.43-1.33) | 0.339 | 13 (1.4%) | 0.52 (0.26-1.02) | 0.058 |
| IVDU | 139 (5.2%) | | | 1.24 (0.74-2.06) | | | 0.416 | 787 (35.4%) | 1.15 (0.74-1.81) | | 0.532 | | | | 96 (5.4%) | 1.47 (0.97-2.24) | 0.070 | 48 (5.3%) | 0.86 (0.54-1.36) | 0.510 |
| Others | 78 (2.9%) | | | 0.84 (0.48-1.46) | | | 0.541 | 219 (9.8%) | 0.85 (0.52-1.41) | | 0.531 | | | | 51 (2.9%) | 1.10 (0.68-1.77) | 0.712 | 32 (3.5%) | 0.96 (0.57-1.62) | 0.894 |
| **Geographic region of origin** |  | | |  | | |  |  |  | |  | | | |  |  |  |  |  |  |
| Portugal\* | 711 (26.8%) | | |  | | |  | 564 (25.3%) |  | |  | | | | 472 (26.8%) |  |  | 244 (26.8%) |  |  |
| Europe | 5 (0.2%) | | | 0.21 (0.08-0.57) | | | 0.002 | 4 (0.2%) | 0.26 (0.09-0.78) | | 0.017 | | | | 4 (0.2%) | 0.36 (0.12-1.08) | 0.069 | 1 (0.1%) | 0.20 (0.03-1.47) | 0.113 |
| Sub-Saharan Africa | 263 (9.9%) | | | 1.00 (0.79-1.25) | | | 0.963 | 212 (9.5%) | 1.03 (0.82-1.28) | | 0.807 | | | | 191 (10.8%) | 1.17 (0.93-1.46) | 0.179 | 59 (6.5%) | 0.60 (0.44-0.81) | 0.001 |
| South America | 30 (1.1%) | | | 1.16 (0.63-2.16) | | | 0.632 | 25 (1.1) | 1.24 (0.69-2.24) | | 0.474 | | | | 20 (1.1%) | 1.11 (0.61-2.01) | 0.735 | 6 (0.7) | 0.56 (0.23-1.33) | 0.189 |
| **Subtypes** |  | | |  | | |  |  |  | |  | | | |  |  |  |  |  |  |
| B\* | 1207 (45.4%) | | |  | | |  | 1055 (47.4%) |  | |  | | | | 767 (43.5%) |  |  | 473 (52.0%) |  |  |
| Non-B | 1020 (38.4%) | | | 0.70 (0.60-0.82) | | | 0.000 | 819 (36.8%) | 0.63 (0.55-0.73) | | 0.000 | | | | 715 (40.6%) | 0.99 (0.86-1.14) | 0.862 | 316 (34.8%) | 0.64 (0.54-0.75) | 0.000 |
| **CD4** (cells/mL) |  | | |  | | |  |  |  | |  | | | |  |  |  |  |  |  |
| <50\* | 214 (8.1%) | | |  | | |  | 166 (7.5%) |  | |  | | | | 162 (9.2%) |  |  | 64 (7.0%) |  |  |
| 51-200 | 572 (21.5%) | | | 0.85 (0.64-1.12) | | | 0.252 | 471 (21.2%) | 1.02 (0.78-1.32) | | 0.912 | | | | 399 (22.6%) | 0.77 (0.59-1.00) | 0.046 | 153 (16.8%) | 0.82 (0.59-1.13) | 0.221 |
| 201-350 | 545 (20.5%) | | | 0.88 (0.66-1.17) | | | 0.376 | 448 (20.1%) | 1.04 (0.80-1.35) | | 0.778 | | | | 358 (20.3%) | 0.70 (0.54-0.91) | 0.009 | 192 (21.1%) | 1.17 (0.85-1.61) | 0.332 |
| 351-500 | 392 (14.8%) | | | 1.22 (0.90-1.66) | | | 0.206 | 328 (14.7%) | 1.37 (1.03-1.82) | | 0.030 | | | | 259 (14.7%) | 0.85 (0.64-1.13) | 0.263 | 139 (15.3%) | 1.34 (0.96-1.88) | 0.084 |
| >501 | 402 (15.1%) | | | 1.08 (0.80-1.47) | | | 0.605 | 356 (16.0%) | 1.46 (1.10-1.93) | | 0.009 | | | | 252 (14.3%) | 0.73 (0.55-0.96) | 0.024 | 156 (17.2%) | 1.45 (1.04-2.02) | 0.027 |
| **Viral Load** (log10 copies/ml) |  | | |  | | |  |  |  | |  | | | |  |  |  |  |  |  |
| < 4.0\* | 1164 (43.8%) | | |  | | |  | 1023(46.0%) |  | |  | | | | 742 (42.1%) |  |  | 410 (45.1%) |  |  |
| 4.1 to 5.0 | 850 (32.0%) | | | 0.70 (0.59-0.83) | | | 0.000 | 706 (31.7%) | 0.67 (0.57-0.78) | | 0.000 | | | | 573 (32.5%) | 0.93 (0.80-1.08) | 0.315 | 302 (33.2%) | 0.89(0.75-1.06) | 0.179 |
| >5.1 | 346 (13.0%) | | | 0.39 (0.32-0.48) | | | 0.000 | 247 (11.1%) | 0.33 (0.27-0.40) | | 0.000 | | | | 257 (14.6%) | 0.75 (0.62-0.90) | 0.003 | 96 (10.6%) | 0.50 (0.39-0.64) | 0.000 |
| **\* Reference category** | |  |  | |  |  |  |  |  |  | |  |  |  | |

****

**Supplementary Figure 1:** Proportion of resistance mutations in sequences (A) drug naïve patients and (B) treated patients between 2001 and 2017

1. Harrel, F. E., 2010. Regression Modelling Strategies: with applications to linear models, logistic regression, and survival analysis, Springer series in statistic. Springer, New York. [↑](#footnote-ref-1)